2026 QMSR Requirements for Foreign Medical Device Manufacturers

Introduction

For foreign medical device manufacturers, QMSR is now an operating requirement rather than a transition project. Teams need to know what changed after February 2, 2026, what an ISO 13485 certificate already covers, what remains FDA-specific, and what happens if their transition work is incomplete.

The immediate test is not whether a manufacturer can show a certificate. It is whether the quality system, records, regulatory interfaces, and FDA-facing responsibilities meet the current version of 21 CFR Part 820 when an inspection or record request begins. FDA QMSR requirements

Who this is for

• Foreign finished-device manufacturers selling or preparing to sell medical devices in the United States.
• Regulatory, quality, and operations leaders who already manage ISO 13485 systems but need to identify the remaining FDA-specific work.
• Teams preparing for establishment registration, device listing, UDI/GUDID work, or inspection readiness alongside a U.S. Agent relationship.
• Manufacturers deciding whether they need inspection coordination, deeper QMS remediation, or both.

What does the QMSR deadline mean for a foreign medical device manufacturer?

Foreign manufacturers subject to FDA device quality requirements must comply with QMSR now. The rule became effective on February 2, 2026, with no continuing transition period, and FDA began enforcing the revised Part 820 framework on that date. FDA QMSR FAQ

• QMSR replaced the prior Quality System Regulation framework in 21 CFR Part 820.
• FDA stopped using QSIT and now conducts device inspections under Compliance Program 7382.850.
• ISO 13485:2016 forms the foundation of QMSR, but FDA-specific statutory and regulatory requirements remain controlling.
• FDA can review management review reports, internal audit records, and supplier audit reports that were previously shielded from routine review under the former regulation.
• Inspection readiness depends on whether the quality system is appropriate for the devices and activities at the site and whether supporting records are complete, current, and retrievable. FDA Compliance Program 7382.850

Is an ISO 13485 certificate enough to meet QMSR now that it is in effect?

No. A current ISO 13485:2016 certificate is a strong starting point, but the certificate does not establish QMSR compliance on its own and does not exempt a manufacturer from FDA inspection. FDA does not require or issue ISO 13485 certificates, and FDA inspections assess compliance with FDA regulations rather than conformity to a certification body’s audit plan. FDA QMSR inspection and certification FAQ

For clauses included within the manufacturer’s certified scope, the practical task is a targeted FDA gap analysis rather than rebuilding the quality system from zero. The table below identifies the ISO foundation and the FDA-specific remainder that a certified foreign manufacturer still needs to address.

Do you need a new quality system audit now that QSR became QMSR?

No automatic new third-party certification audit is required solely because QSR became QMSR. MDSAP remains voluntary, FDA does not require an ISO 13485 certificate, and an existing certificate does not need to be replaced merely because FDA renamed and revised Part 820.

What most manufacturers do need is a documented comparative assessment that maps their existing procedures and records to QMSR. That assessment is not a substitute for an internal audit, certification audit, or FDA inspection. It is the working document that identifies procedure changes, form changes, training needs, record gaps, and FDA-specific controls before an investigator asks for them. FDA inspection preparation guidance

FDA now uses Compliance Program 7382.850 rather than QSIT. The practical burden is demonstrating that management oversight, design and development, production controls, complaint handling, CAPA, supplier controls, and postmarket obligations operate as linked processes supported by usable records. FDA device inspection program

What happens if a device company missed the February 2026 QMSR deadline?

There is no remaining transition period. A manufacturer that has not completed its QMSR transition should treat the work as active remediation and inspection readiness, not as a future implementation project. FDA investigators can review records created before February 2, 2026, and FDA recommends a comparative analysis showing how those records meet the current requirements. FDA QMSR records FAQ

1. Complete a clause-by-clause comparison of the existing QMS against ISO 13485:2016 and the supplemental FDA requirements in 21 CFR Part 820.
2. Revise affected procedures, forms, definitions, complaint workflows, MDR decision points, labeling controls, and UDI records.
3. Train responsible personnel and document the effective date of each corrected process.
4. Stage management review, audit, supplier, design, complaint, CAPA, servicing, and production records for prompt retrieval.
5. Verify that establishment registration, device listings, U.S. Agent information, and device identifiers remain accurate while QMS work proceeds.

Failure to comply with an applicable QMSR requirement renders the affected device adulterated under section 501(h) of the FD&C Act and can support inspection findings or regulatory action. Missing the transition date does not automatically cancel a 510(k) clearance or place a firm on an import alert, but it does leave the manufacturer exposed under the current inspection program. FDA Compliance Program 7382.850

Inspection refusal creates a separate and more direct import consequence. A foreign device manufacturer that refuses to permit the initiation or completion of an FDA inspection can be placed on the Red List under Import Alert 89-16. Products from listed firms are subject to detention without physical examination and refusal of admission until the inspection-refusal condition is resolved. FDA Import Alert 89-16

Management responsibility still matters, and it is visible in records

Senior management ownership did not become less important under harmonization. QMSR makes weak executive control visible because FDA can evaluate whether the quality management system is maintained, resourced, reviewed, and acted on as a management system rather than a documentation library. Manufacturers must establish and maintain a quality management system appropriate to their devices and activities. FDA Compliance Program 7382.850

For foreign firms, this usually shows up in three places: whether management review outputs drive decisions, whether quality issues escalate across functions, and whether regulatory actions have accountable owners. Thin or disconnected records make it difficult to demonstrate that management oversight controls the actual product and process risks.

Design and development applicability is broader than some teams assume

Design and development controls remain a live issue under QMSR. Devices manufactured under an investigational device exemption are not exempt from the design and development requirements in 21 CFR 820.10(c) and ISO 13485 Clause 7. Startups and fast-moving product teams should not defer design controls until commercialization is close. FDA QMSR applicability guidance

Where design and development requirements apply, the records around inputs, outputs, reviews, verification, validation, transfer, risk management, and change control need to hold together. This is especially important for IVD, software as a medical device, and iterative device portfolios where changes can outpace the underlying file set. FDA design and development inspection instructions

How does QMSR affect an existing 510(k) clearance?

QMSR does not reopen, cancel, or require resubmission of an existing 510(k) solely because the quality system regulation changed. The clearance remains the marketing authorization for the device as cleared, while QMSR governs the quality system used to design, manufacture, label, store, install, and service that device.

A new 510(k) becomes relevant when the manufacturer changes the device, intended use, specifications, software, labeling, or manufacturing process in a way that could significantly affect safety or effectiveness. The QMSR transition itself is not such a device change. Manufacturers should document transition-related procedure changes through their quality system and separately evaluate substantive device changes under FDA’s 510(k) modification framework. FDA 510(k) modification guidance

Complaint handling and CAPA are still the system’s stress test

Complaint files remain a distinct FDA concern even where a device has a CGMP exemption. QMSR retains ISO 13485 complaint handling as the foundation and adds specific FDA complaint-record requirements under 21 CFR 820.35. In practice, complaint handling remains one of the clearest windows into whether the quality system is functioning or merely documented. FDA complaint-file requirements under QMSR

The interface between complaints, MDR assessment, nonconformance, risk management, and CAPA is usually the more revealing test. Regulatory support buyers should distinguish FDA-facing coordination from internal remediation of root-cause analysis, investigation quality, or CAPA effectiveness. Those needs are related, but they are not the same service. FDA Medical Device Reporting guidance

U.S. Agent inspection coordination is not the same as QMS consulting

A foreign medical device establishment must identify a U.S. Agent. The defined role includes assisting FDA communications, responding to questions about imported devices, helping schedule inspections, and receiving information when FDA cannot reach the foreign establishment directly or expeditiously. The manufacturer remains responsible for its quality system, MDR decisions, and 510(k) submissions. FDA medical device U.S. Agent responsibilities

FDA Entry Point supports the FDA-facing layer by coordinating inspection communications, relaying correspondence, maintaining U.S. Agent coverage, and helping keep establishment registration and device listing information accurate. It also supports device listing and UDI/GUDID coordination. FDA Entry Point U.S. Agent services

A U.S. Agent does not build, remediate, or certify the manufacturer’s quality management system by default. Internal QMS architecture, design-control remediation, complaint-system redesign, CAPA overhaul, and full ISO 13485 implementation require a qualified QMS consultant or internal quality team. Inspection coordination and quality-system remediation should be assigned separately, even when both are needed at the same time. FDA Entry Point medical device registration guidance

FDA Entry Point is the best fit when…

• Your device company needs a U.S. Agent plus establishment registration, device listing, or UDI/GUDID support under one relationship rather than a mailbox-only contact. FDA Entry Point medical device listing support
• Your regulatory and quality teams own the QMS remediation but need dependable FDA communication handling, registration accuracy, and inspection coordination for a foreign establishment.
• You are a startup or mid-size foreign manufacturer without U.S.-based regulatory infrastructure and need one accountable partner for the FDA-facing mechanics around market access. FDA Entry Point company profile

FDA Entry Point is not a fit when…

• Your main problem is rebuilding the quality system itself rather than managing the FDA-facing U.S. Agent, registration, listing, and communication layer.
• You need a full ISO 13485 implementation, internal audit program design, or deep CAPA and design-control remediation led inside your QMS.
• You need a certification body to issue an ISO conformity certificate. FDA does not require or issue ISO 13485 certificates for QMSR compliance. FDA QMSR certification FAQ

Common pitfalls under QMSR

• Treating ISO certification as proof that FDA inspection readiness is complete.
• Commissioning an unnecessary replacement certification audit instead of first completing a focused FDA gap assessment.
• Assuming the old QSIT structure still predicts how FDA will inspect after February 2, 2026.
• Reapplying for an unchanged 510(k) because Part 820 changed rather than separating quality-system transition work from device modifications.
• Keeping complaint, MDR, CAPA, risk, and design-change records in separate systems that do not reconcile cleanly.
• Confusing U.S. Agent designation with broader QMS consulting and discovering the gap only when an inspection or quality event begins.

Frequently asked questions

Does QMSR apply to foreign manufacturers in the same way it applies to U.S. manufacturers?

Yes. QMSR applies to finished devices imported or offered for import into the United States, and foreign manufacturing sites are subject to FDA quality-system requirements and inspection. The foreign location does not create a separate transition date or a general exemption from Part 820. FDA medical device import requirements

Can records created before February 2, 2026 still support a QMSR inspection?

Yes. FDA investigators can review quality-system records created before February 2, 2026. Manufacturers should preserve those records and use a documented comparison to show how the earlier procedures and records satisfy current QMSR requirements. Where a gap exists, the remediation record should identify the correction, responsible owner, implementation date, and supporting training or effectiveness evidence. FDA QMSR records guidance

Does MDSAP participation prevent FDA from inspecting a foreign device manufacturer?

No. MDSAP participation does not remove FDA’s inspection authority. Actively enrolled manufacturers are generally not selected for baseline surveillance inspections, but FDA can still conduct for-cause, compliance follow-up, specific product risk, or PMA-related inspections. FDA inspections also follow FDA’s QMSR program rather than the MDSAP audit plan. FDA Compliance Program 7382.850

Does a medical device U.S. Agent take responsibility for MDR reports or 510(k) submissions?

The manufacturer retains responsibility for MDR compliance and 510(k) submissions. A medical device U.S. Agent assists FDA communications, answers questions about imported devices, helps schedule inspections, and receives correspondence when FDA cannot promptly reach the foreign establishment. FDA Entry Point can coordinate that communication flow while the manufacturer’s regulatory and quality teams make the underlying reporting, submission, and remediation decisions. FDA U.S. Agent role

References

• FDA: Quality Management System Regulation
• FDA: QMSR Frequently Asked Questions
• FDA: QMSR Final Rule
• FDA: Inspection of Medical Device Manufacturers Compliance Program 7382.850
• FDA: Import Alert 89-16
• FDA: When a Device Modification Requires a New 510(k)
• FDA: Medical Device U.S. Agents
• FDA: Medical Device Reporting for Manufacturers
• FDA Entry Point: U.S. Agent Services
• FDA Entry Point: Medical Device Listing and UDI Support